“invivodata was able to deliver us the real-time data that we needed to develop an unbiased view into our patients’ pain experiences. This kind of data cannot be collected with paper diaries.”
Dr. Michael Gendreau
Chief Medical Officer, Cypress Bioscience
invivodata Recognized as a Top 50 Life Science Firm
- March 23, 2006
invivodata Recognized as a Top 50 Life Science Firm by Bio-IT World
Company's scientific and regulatory leadership cited as key components of eDiary offering
PITTSBURGH — March 23, 2006 — invivodata® inc., the industry leader in electronic patient reported outcomes (ePRO) solutions for global clinical research, today announced that it has been named to Bio-IT World’s inaugural “Bio-IT 50” compendium. The list includes its editors’ picks of the top 50 life sciences firms that provide the most indispensable, enabling technologies to the biopharma industry.
Described as one of the companies driving the future of biomedical research and drug discovery, invivodata was selected based on the company’s scientific and regulatory leadership in the field of ePRO data capture. invivodata’s extensive peer-reviewed publications have helped showcase the inadequacy of paper diaries and influence the worldwide adoption of eDiaries. In addition, invivodata is the only eDiary company that can identify two FDA approvals that depended on its system, demonstrating the maturity of the system and its ability to withstand regulatory scrutiny.
“We are honored to be included in this list of best-of-class companies in the industry,” said Doug Engfer, president and CEO of invivodata. “In light of the FDA’s recently issued draft guidance on Patient Reported Outcomes (PROs) in medical research development, trial sponsors are recognizing that scientific principles must be instilled in any technology that is going to deliver high-integrity PRO data. It’s truly rewarding to be recognized as a leader for the scientific advances we have made in this field, and continue to apply to our unique ePRO solution.”
About invivodata inc.
invivodata combines behavioral science, information technology and clinical expertise to capture the highest-quality electronic Patient Reported Outcome (ePRO) data in clinical research. The invivodata solution, which includes DiaryPRO for real-time PRO data collection and SitePRO™ for site-based PRO data collection, is based on patented compliance methods that include a proven patient management system that gives researchers and sponsors visibility into study progress and improves trial efficiencies. Strengthened by its regulatory and scientific expertise, invivodata is the industry-leading eDiary provider for delivering primary efficacy data for FDA approvals. Its solutions have been used in 140 clinical trials worldwide by more than 55,000 patients, collecting over 89 million patient-initiated entries for studies in over 65 disease states. invivodata’s scalable business model enables it to satisfy diverse client needs and meet the increasing global demand for its innovative solutions. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters are in London, England; and its technology development center is in Scotts Valley, Calif., USA.
